Flash freestyle software

Now available for iPhone and Android. With the LibreLinkUp app, get glucose readings sent to your phone from family and friends who use the FreeStyle LibreLink mobile app 2. You and your child 2 can manage diabetes better together with more complete glucose information with the FreeStyle Libre system.

The FreeStyle Libre flash glucose monitoring system is designed to liberate patients from the hassles of glucose monitoring. Our support section will guide you through the most commonly asked questions regarding the FreeStyle Libre system or visit one of our Experience Centres to get one-to-one support.

FreeStyle LibreLink is a mobile application. FreeStyle Libre readers and sensors are provided by Abbott. Please note that our Customer Care Centre is closed on public holidays.

New customers only. Cancel anytime. Learn more. FreeStyle Libre uses cookies to give you the best website experience. By using our website, you consent to the use of cookies. More about our privacy policy. The FreeStyle Libre flash glucose monitoring system is indicated for measuring interstitial fluid glucose levels in people age 4 and older with diabetes mellitus.

The indication for children age 4 — 17 is limited to those who are supervised by a caregiver at least 18 years old who is responsible for supervising, managing, and assisting the child in using the FreeStyle Libre system and interpreting its readings. Health care professionals and consumers should be aware about the limitations of available scientific evidence for use of this device in any other groups of patients who require diabetes management.

Always read the label and use as directed. All Rights Reserved. FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. Please read legal notice for further details No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott Healthcare Private Limited, except to identify the product or services of the company.

This website and the information contained herein is intended for use by residents of India. The product images are for illustrative purposes only. Disclaimer www. If you are resident of another country, please contact your local Abbott affiliate to obtain the appropriate product information for your country of residence.

The "Yes" link below will take you to a website other than Abbott Laboratories. Links to other websites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the content of such websites or any link contained in such websites.

Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement by Abbott Laboratories of the site. If you live in another country, please contact your local Abbott office to obtain the correct product information for your country of residence. FreeStyle Libre Sensor. FreeStyle Libre Reader. FreeStyle Libre Pro. FreeStyle Optium Neo. Getting started.

FreeStyle Libre application. Reading your glucose levels. Time in Range. Clinical Benefits. Also, we found several publications investigating the accuracy of the device, however, the study designs of these studies single arm did not meet the inclusion criteria of this evaluation and, although we compiled them for information, they were excluded from the synthesis. The information derived from these single arm studies are potentially important to validate the sensitivity and specificity estimates of FreeStyle Libre.

In addition, we found other European assessments conducted in the past 6 to 8 months. The included RCTs reported data on middle aged adults from European countries with type 1 and 2 DM at 6 months post intervention. Main findings from these trials are that FreeStyle Libre may slightly improve treatment satisfaction, time spent with glucose in range 3. The submitted economic model runs a year time horizon. The submitter's basecase suggested that the technology is dominant for individuals with type 1 DM, i.

As the model received by the submitter was neither sufficiently transparent nor sufficiently flexible to allow changes, we have not been able to produce alternative incremental cost-effectiveness ratios ICERs. From a healthcare perspective, the submitter has calculated a budget impact for type 1 DM to have a total added cost the fifth year after adoption of the technology.

Further, the submitter calculated a budget impact for type 1 and 2 DM that lead to a cost saving on the fifth year after adoption of the techonology. The submitter did not calculate a budget impact for type 2 DM only. We estimated that, from a healthcare perspective, the annual costs five years after introduction would be NOK million added cost and NOK Conclusions: Overall, the evidence for the intervention of interest was limited but suggests that FreeStyle Libre increases treatment satisfaction, reduces some hypo- and hyperglycaemic measures increases time with glucose in range 3.

The quality of the included studies was generally low and there were only two small studies including middle aged adults.